Among the various bacterial infections, tuberculosis continues to hold center stage. Its
causative agent, Mycobacterium tuberculosis, possesses robust defense mechanisms …

New drugs with new mechanisms of action are urgently required to tackle the global
tuberculosis epidemic. Following the FDA-approval of the ATP synthase inhibitor …

Mycobacterial energy metabolism currently attracts strong attention as new target space for
development of anti-tuberculosis drugs. The imidazopyridine Q203 targets the cytochrome …

Quinoline and its derivatives comprise an important group of heterocyclic compounds that
exhibits a wide range of pharmacological properties such as antibacterial, antiviral …

Abstract The Pathogen Box is a 400‐strong collection of drug‐like compounds, selected for
their potential against several of the world's most important neglected tropical diseases …

Causing approximately 10 million incident cases and 1.3–1.5 million deaths every year,
Mycobacterium tuberculosis remains a global health problem. The risk is further …

New drugs are needed to control the current tuberculosis (TB) pandemic caused by infection
with Mycobacterium tuberculosis. We report here on our work with AX-35, an …

Using a classical molecular simplification approach, a series of 36 quinolines were
synthesized and evaluated as in vitro inhibitors of Mycobacterium tuberculosis (M …

Tuberculosis (TB) remains one of the leading infectious disease killers in the world. The
ongoing development of novel anti-TB medications has yielded potent compounds that often …

Using cycloalkyl and electron-donating groups to decrease the carbonyl electrophilicity, a
novel series of 2-(quinoline-4-yloxy) acetamides was synthesized and evaluated as in vitro …